Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS) a double-blind, randomised controlled trial /
BACKGROUND: Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-p...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
The Lancet Publishing Group
2016
|
| Sorozat: | LANCET
387 No. 10021 |
| doi: | 10.1016/S0140-6736(15)01129-0 |
| mtmt: | 3257984 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/11864 |